Sign in

CIK 0001907108

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Lexeo Therapeutics, Inc.

Sign in to watch
Ticker
LXEO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
854012572
Phone
+1 212-547-9879
Business address
345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK, NY, 10010
  1. 4 Derivatives Options or other derivatives
  2. 4 Planned sale Chief Executive Officer sold 2,500 shares at $7.82 ($19,557)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Planned sale Chief Executive Officer sold 5,000 shares at $8.10 ($40,496)
  5. 4 Planned sale Chief Executive Officer sold 5,000 shares at $10.65 ($53,274)
  6. 4 Planned sale Chief Executive Officer sold 5,000 shares at $11.53 ($57,635)
  7. 4 Planned sale Chief Executive Officer sold 55,000 shares at an average $16.79 ($923,388)
  8. 4 Derivatives Options or other derivatives
  9. 3 Insider Initial Statement of Ownership
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Grant or award Chief Technical Officer acquired 31,250 shares (grant or award)
  16. 4 Planned sale Chief Executive Officer sold 5,000 shares at an average $17.65 ($88,264)
  17. 3 Insider Initial Statement of Ownership
  18. 4 Planned sale Chief Executive Officer sold 5,000 shares at $13.22 ($66,093)
  19. 3 Insider Initial Statement of Ownership
  20. 4 Derivatives Options or other derivatives

Page 5 of 7 · 121 filings